Last updated: April 23, 2026
What protection does AU2011304285 claim, and how does it position across the Australian drug patent landscape?
AU2011304285 is an Australian patent application that maps to the AU system’s standard “substance” protection pattern for small-molecule drugs: it typically claims one or more pharmaceutical compositions and/or specific compounds, supported by method-of-treatment and/or use claims. It also functions as a linkage point for later national-phase/continuation filings and for patent term strategy in Australia through the country’s patent term and patent-term-extension framework for medicines.
Scope and claim structure in AU2011304285 (Australia-specific)
AU2011304285 fits the Australian practice for drug filings where the claim set usually includes:
What the claim scope is intended to cover (practical boundaries)
In Australia, infringement analysis for drug patents centers on whether a product or treatment falls within the literal claim scope and whether “dosage/use” claims are met in real-world prescribing and administration. For AU2011304285, the functional risk perimeter usually includes:
- any manufacture/sale/import activity that produces a claimed composition or a product that contains the claimed compound (product/composition claim pathway), and
- any clinical use that matches the claimed therapeutic use language (use/method-of-treatment pathway).
What does the Australian landscape look like around AU2011304285 (FTO and blocking points)?
1) Likely enforcement vectors in Australia
For an application like AU2011304285, the Australian enforcement playbook generally prioritizes:
- Composition and compound claims as they support conventional infringement theories for generics and importers.
- Method/use claims as they can attach to prescribing practices where evidence supports that the patented treatment is used.
2) Patent term management in Australia
Australia’s drug landscape is shaped by three mechanisms that determine practical “blocking time”:
- Standard patent term: 20 years from the priority date (subject to maintenance and other conditions).
- Patent term extensions (PTE): for eligible medicines to compensate for regulatory delay, subject to eligibility and filing/requirements.
- Linkage and regulatory listing: the TGA listing framework can align marketing approvals with patent expiry and enforcement posture.
AU2011304285’s real-world blocking value depends on whether it includes claims that are eligible for listing/extension under Australia’s medicine-related patent frameworks and whether the patent in question is granted and maintained.
3) Typical adjacent portfolios that co-exist
In a mature drug class/target space, Australian filings commonly cluster into:
- Primary drug substance patents (compound and composition).
- Second-wave formulation patents (controlled release, particle size, polymorph handling, stability).
- Combination/indication patents (new indications, lines of therapy, co-administered agents).
- Process patents (manufacturing steps and intermediates).
AU2011304285’s landscape positioning depends on whether it is a first-wave substance filing or a later-wave improvement/indication filing. The scope and claim layering described above aligns with either scenario, but the enforcement focus in Australia will differ by claim type: product/composition blocks manufacturing; use claims block prescribing.
How broad are the claims in AU2011304285 likely to be (and what narrows them)?
Claim breadth drivers (what widens coverage)
- Genus-style compound claims (if the spec supports a class defined by substituents or parameters) typically broaden coverage across analogs.
- Composition claims not tied to specific excipients can cover many formulation variants if structurally and functionally supported.
- Use claims with broad indication language increase coverage.
Claim narrowing drivers (what reduces coverage)
- Tight structural definitions (specific compounds, specific substitutions) reduce reach.
- Polymorph/salt dependence if only particular forms are enabled in the spec and claimed.
- Regimen specificity in dosage/use dependent claims reduces coverage to prescribing patterns that match the claim.
Core take: practical scope is claim-definition dependent
In Australia, the scope you can rely on for FTO is the exact wording of AU2011304285’s independent claims. Dependent claims narrow by definition; broadest independent claim(s) anchor FTO.
Where does AU2011304285 sit relative to competitors and generic entry risk in Australia?
1) Competitive threat pattern
In markets where AU filings exist, generic entry risk typically peaks when:
- the substance/composition claims are near expiry or invalidated, or
- the remaining enforceable claims shift to high-specificity use/regimen/combination coverage.
2) How this plays out for typical Australian FTO
- If AU2011304285 includes compound/composition claims covering the active ingredient and standard formulation forms, then generic entry is more constrained.
- If enforceable claims are mainly indication/use and tied to a narrow regimen, generic entry may occur with label carve-outs or through non-infringing prescribing patterns.
3) Key landscape question for decision-makers
The decision-relevant outcome is whether the claims in AU2011304285 cover:
- the active ingredient itself,
- a pharmaceutical composition intended for market,
- and/or a therapeutic use that maps to the approved TGA indication and typical clinical practice.
What does the patent landscape imply for freedom-to-operate in Australia?
FTO outcome mapping (claim-type based)
- Compound/composition blocking: high risk for generic manufacturers and parallel importers if the generics would fall within composition definitions.
- Method/use blocking: high risk for commercialization if promotion or prescribing aligns with claimed indications/regimens.
- Combination therapy claims: risk concentrates on co-administration products or branded combination therapies.
Practical FTO posture in Australia
Given Australia’s enforcement climate, FTO typically uses:
- claim charting of independent claims,
- assessment of whether likely marketed products match composition definition and/or use language,
- evaluation of whether any non-infringing alternatives exist by avoiding claimed formulation features or avoiding claimed indications/regimens.
How should investors and R&D teams use AU2011304285 in portfolio and diligence?
1) Patent due diligence checkpoints
For any investment or R&D decision tied to an Australian medicine portfolio, AU2011304285 should be assessed on:
- whether it is granted vs still pending,
- whether it has active status (renewal/maintenance),
- whether it has an eligible path for patent term extension (where applicable),
- the relationship between independent claims and the company’s commercial product form (active ingredient, salt/polymorph, formulation, dosage, indication).
2) Portfolio strategy implications
If AU2011304285 is a substance/composition anchor, later filings can extend enforceability via:
- additional formulations,
- additional indications,
- specific combinations.
If AU2011304285 is narrower (use/regimen-limited), it can be complemented by broader substance/composition patents already in the portfolio.
Key Takeaways
- AU2011304285’s claim set in Australian drug practice is structured to protect the drug entity and/or pharmaceutical compositions and to cover therapeutic uses via method-of-treatment/second medical use claims.
- Australia’s enforcement risk is typically driven by whether the independent claims align with the marketed active ingredient/formulation and with approved or actual therapeutic use patterns.
- Blocking power depends on grant status, maintenance, and eligibility for medicine-related term strategy, which can extend the period during which composition and use claims matter for generic entry.
- In FTO and diligence, AU2011304285 is most decisive when its independent claims match real commercial product features (salt/polymorph, formulation, dosage, and indication).
FAQs
1) What claim types usually matter most for generic FTO in Australia?
Compound and pharmaceutical composition claims usually drive infringement risk for generics and parallel imports; method-of-treatment/use claims drive prescribing-related risk.
2) Do dependent claims narrow risk immediately?
Dependent claims narrow coverage by definition. Independent claims set the base scope; dependent claims can still block specific regimens or combinations if they are directly practiced.
3) How do patent term extensions affect AU drug patents?
If a medicine qualifies, patent term extension can extend practical exclusivity beyond the standard term, maintaining enforceability for relevant claims.
4) What determines whether AU2011304285 blocks a product at launch?
Whether the marketed product falls within composition/compound definitions and whether prescribing aligns with any claimed therapeutic use/regimen.
5) How should investors diligence AU drug filings?
Focus on grant status, active maintenance, claim scope relative to the commercial product, and whether any extension/listing mechanisms apply to the relevant claims.
References
[1] Australian Patent Office (IP Australia). “Australian patents: Search and view documents (Patents)”. IP Australia. https://www.ipaustralia.gov.au/
[2] Therapeutic Goods Administration (TGA). “Australian medicines and regulatory information”. Australian Government. https://www.tga.gov.au/
[3] Australian Government. “Patents Act 1990” (Cth). Federal Register of Legislation. https://www.legislation.gov.au/
[4] IP Australia. “Guidelines for Patent Examiners: Patent term and extensions / medicine-related framework (where applicable)”. https://www.ipaustralia.gov.au/
